Kamada Ltd. · NASDAQ:KMDA
Kamada — Investor Presentation (January 2026)
21 slides from Kamada's investor presentation, Jan 7, 2026
Slide 1: Corporate Presentation January 2026
Corporate Presentation January 2026 TURNING STRATEGIC DRIVERS INTO PROFITABLE GROWTH NASDAQ: KMDA; TASE: KMDA.TA
Slide 2: Forward-Looking Statement
2 FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . This presentation contains forward - looking statements, which express the current beliefs and expectations of Kamada’s management . Such statements include 2025 and 2026 financial guidance ; gr
Slide 3: Kamada - A Global Biopharmaceutical Company
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 14 % CAGR (from 2021) $ 200 - 205M 1 2026 Revenues Guidance $ 50 - 53M 1 2026 Adj. EBIDTA Guidance 4 Growth Drivers A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF M
Slide 4: Global Commercial Footprint
GLOBAL COMMERCIAL FOOTPRINT United States Israel UAE Focused on lifecycle management and expansion to new markets, mainly in the MENA and LATAM regions Commercial operations in the US with seasoned staff, experienced in specialty plasma products Corporate offices in Israel , US and UAE; key markets
Slide 5: Experienced Leadership
5 EXPERIENCED LEADERSHIP Amir London CEO Hanni Neheman VP Marketing & Sales Liron Reshef VP Human Resources Shavit Beladev VP Kamada Ɗ Plasma Chaime Orlev CFO Jon Knight VP U.S Commercial Yael Brenner VP Quality Boris Gorelik VP Business Development & Strategic Programs Nir Livneh VP Legal, General
Slide 6: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS 6
Slide 7: Annual Double-Digit Growth Trajectory
7 ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY 6 18 24 34 40 - 44 50 - 53 2021 2022 2023 2024 2025 2026 104 129 142 161 178 - 182 200 - 205 2021 2022 2023 2024 2025 2026 ADJUSTED EBITDA US$M 53 % CAGR 2025 and 2026 represents annual guidance 2025 and 2026 represents annual guidance REVENUES US$M 14 % CAG
Slide 8: 9M-2025 Continuing the Growth
8 9 M - 2025 CONTINUING THE GROWTH YoY DOUBLE DIGIT REVENUE AND PROFITABILITY INCREASE Paid special cash dividend of $ 0.20 per share (totaling approximately $ 11.5 M) on April 7 , 2025 GROSS PROFIT REVENUE 12% 2024 $52.9 2025 $ 59.4 11% 2024 $121.9 2025 $ 135.8 Adj. EBITDA EPS 35% 2024 $25.4 2025 $
Slide 9: Kamada's Roadmap for Continued Annual Double-Digit Profitable Growth
9 KAMADA ’ S ROADMAP FOR CONTINUED ANNUAL DOUBLE - DIGIT PROFITABLE GROWTH Specialty Plasma Therapies Portfolio of 6 FDA - approved products marketed in over 30 territories In - licensing Partnerships Commercialization & Distribution of third parties ’ biopharmaceutical products in Israel & MENA Pla
Slide 10: A Global Leader in Anti-Rabies Immune Globulin (HRIG)
$ 150 M Estimated total U.S HRIG market size Only anti - Rabies IgG product with FDA approved label confirming safety and effectiveness in children KEDRAB /KAMRAB $ 50 M 2024 U.S. Revenues; $ 135 M Minimum sales in the U.S. expected in 2025 - 2027 Only 2 FDA approved products Leading HRIG in Canada,
Slide 11: GLASSIA Liquid AAT for the Treatment of AATD
11 GLASSIA LIQUID AAT FOR THE TREATMENT OF AAT DEFICIENCY (AATD) Out - licensed to Takeda for distribution in the USA, Canada, Australia and New Zealand ; Royalties income from Takeda at a rate of 6 % ; 2026 royalties' income expected at approximately $ 10 M ; growing 5 % - 8 % per year thereafter t
Slide 12: CYTOGAM CMV Immune Globulin
12 CYTOGAM CMV IMMUNE GLOBULIN 1. Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) CYTOGAM is the only plasma - derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause for organ rejectio
Slide 13: In-Licensing Products Growth
13 IN LICENSING PRODUCTS GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES EXPANDING THE DISTRIBUTION BUSINESS TO THE MENA REGION Key areas : pl
Slide 14: Plasma Sales Expanding Vertical Integration & Revenue Growth
14 PLASMA SALES EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Operating three plasma collection centers in Texas; Houston, San Antonio and Beaumont Houston center approved by th
Slide 15: New M&A Opportunities
15 NEW M&A OPPORTUNITIES EXPECT TO SECURE NEW M&A TRANSACTIONS IN 2026; LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Screening strategic business development opportunities to identify potential acquisition to accelerate long - term growth Focusing on products synergistic to ou
Slide 16: Delivering on Our Commitments
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 14 % CAGR (from 2021) $ 200 - 205M 1 2026 Revenues Guidance $ 50 - 53M 1 2026 Adj. EBIDTA Guidance 4 Growth Drivers DELIVERING ON OUR COMMITMENTS $ 7 đ .0 M Unaudited Cash (Dec
Slide 17: Thank You
THANK YOU www.kamada.com NASDAQ: KMDA; TASE: KMDA.TA
Slide 18: Strong 9M-2025 Financial Results Details
18 Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses STRONG 9 M - 2025 FINANCIAL RESULTS DETAILS FY 2024 Q3/24 Q3/25 9M/24 9 M/ 25 US $ M Increase driven
Slide 19: Non-IFRS Measures – Adjusted EBITDA
19 NON - IFRS MEASURES – ADJUSTED EBITDA Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (v) non - cash share - based compensation expenses FY 2024 Q 3 / 24 Q 3 / 25 9 M/ 24 9 M/ 25 US $ M 14.5 3.9 5.3
Slide 20: FDA-Approved Specialty Plasma Products
20 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of
Slide 21: Immune Globulin (IgG) Manufacturing
21 IMMUNE GLOBULIN (IgG) MANUFACTURING Some of the photos by Unknown Author are licensed under CC BY - NC - ND 02 Plasma Screening: High Titer Antibodies 03 Plasma Fractionation Purification process 01 Plasma Collection in the United States 04 Viral Inactivation and Reduction 05 Formulation and Fina